NCT07070479: Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
- State
- Under way
- Phase
- Phase 2
- People
- 208 planned
- Started
- 24 Jun 2025
- Primary completion
- 30 Jan 2027
- Arms
- Ivonescimab plus Nimotuzumab
- Results
- None posted
- 24 Jun 2025: Trial started
- 17 Jul 2025: Trial registered